Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 8, 2026Cancer ScienceOpen Access

Treatment‐Free Remission in Chronic Myeloid Leukemia: Toward Precision and Personalized Approaches to Functional Cure

View Full Paper
Ask AI
Bookmark
Share

Authors

HUHiroshi UreshinoSKShinya Kimura

Discussion

Loading...

Member takes

Overview

Review uncovers immune and stem cell determinants of treatment-free remission in chronic myeloid leukemia, highlighting the necessity of integrated precision models for functional cure.

Key Points

  • To review the biological mechanisms governing treatment-free remission after tyrosine kinase inhibitor cessation and outline precision biomarker strategies for achieving functional cure in chronic myeloid leukemia.
  • Synthesized molecular and immunological evidence on leukemic stem cell persistence and host immune control following tyrosine kinase inhibitor discontinuation in chronic-phase disease.
  • Evaluated the biomarker utility of natural killer cells, adaptive T-cell responses, immunogenetics, and residual stem cell survival pathways.
  • Natural killer cell abundance, maturation, and killer immunoglobulin-like receptor–human leukocyte antigen immunogenetics demonstrate the most consistent biological associations with sustained treatment-free remission.
  • Persistent leukemic stem cells drive molecular relapse through BCR::ABL1-independent signaling, immune-evasion mechanisms, and sanctuary within the protective bone marrow niche.
  • Single biomarkers lack sufficient predictive accuracy, necessitating integrated precision models that combine clinical metrics, residual disease depth, immunogenetics, and stem cell biology.

Cite This Study

Ureshino et al. (2026) studied this question.

synapsesocial.com/papers/6a9fd78a58e84d0ff5b464cchttps://doi.org/10.1111/cas.70532
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Treatment-Free Remission and Immune Profiling after Frontline Second-Generation TKI Therapy in CML2026 · 1 citations
  2. 2A Higher Neutrophil Count Is Associated with Favorable Achievement of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia Who Received Second Generation Tyrosine Kinase Inhibitor as Frontline Treatment2024 · 1 citations
  3. 3Five-year interim analysis of J-SKI: an observational study of TKI discontinuation in patients with CML in Japan2026
  4. 42025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia2025 · 126 citations
  5. 5Innate or Adaptive Immunity? The Example of Natural Killer Cells2011 · 2,814 citations